$ZEOX

BESPOKE TRICYCLES INC

CIK:0001557376|SEC Filings

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Apr. 30, 2026	Apr. 30, 2025	Apr. 30, 2026	Apr. 30, 2025
Income Statement [Abstract]
Revenues (includes sales to related parties of approximately $30,000, $43,000, $30,000, and $75,000, respectively)	$ 2,581,000	$ 1,149,000	$ 4,027,000	$ 2,239,000
Cost of revenues	526,000	256,000	807,000	447,000
Gross profit	2,055,000	893,000	3,220,000	1,792,000
General and administrative expenses	2,567,000	2,287,000	4,610,000	4,439,000
Loss from operations	(512,000)	(1,394,000)	(1,390,000)	(2,647,000)
Other income (expense)
Gain on sale of Exotropin interests	390,000		390,000
Interest expense	(11,000)	(21,000)	(20,000)	(43,000)
Change in obligation to repurchase shares	(17,000)		2,000
Other income	5,000	24,000	21,000	56,000
Net loss	$ (145,000)	$ (1,391,000)	$ (997,000)	$ (2,634,000)
Net loss per common share - basic	$ (0.02)	$ (0.22)	$ (0.14)	$ (0.42)
Net loss per common share - diluted	$ (0.02)	$ (0.22)	$ (0.14)	$ (0.42)
Weighted average number of common shares outstanding - basic	7,757,469	6,344,817	7,383,436	6,344,817
Weighted average number of common shares outstanding - diluted	7,757,469	6,344,817	7,383,436	6,344,817

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Apr. 30, 2026	Apr. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (997,000)	$ (2,634,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	38,000	34,000
Amortization of OID and commitment fee discount – Promissory notes	4,000	12,000
Stock-based compensation	1,182,000	2,187,000
Gain on sale of Exotropin interests	(390,000)
Change in obligation to repurchase shares	(2,000)
Changes in operating assets and liabilities:
Accounts receivable, net of allowance for bad debts	(241,000)	183,000
Other receivable		2,000
Prepaid expenses	(179,000)	3,000
Inventories	(313,000)	(2,000)
Accounts payable and accrued expenses	227,000	165,000
Security deposits	(11,000)
Deferred revenue	73,000	(28,000)
Net cash used in operating activities	(609,000)	(78,000)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of fixed assets	(78,000)
Proceeds from sale of Exotropin interests	376,000
Net cash provided by financing activities	298,000
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of common stock	1,950,000
Payments on finance leases	(14,000)	(37,000)
Net cash provided by (used in) financing activities	1,936,000	(37,000)
Increase (decrease) in cash	1,625,000	(115,000)
Cash at beginning of period	221,000	657,000
Cash at end of period	1,846,000	542,000
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for taxes
Cash paid for interest
NON-CASH INVESTING AND FINANCING TRANSACTIONS:
Reduction in royalty payable through transfer of inventory	50,000
Reduction in liability from sale of Exotropin interests	14,000
Finance lease obligations		$ 125,000

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Apr. 30, 2026	Oct. 31, 2025
Current Assets
Cash	$ 1,846,000	$ 221,000
Accounts receivable, net of allowance for bad debts	276,000	35,000
Prepaid expenses	458,000	279,000
Inventories	686,000	423,000
Total Current Assets	3,266,000	958,000
Property and equipment, net	609,000	569,000
Security deposit	11,000
TOTAL ASSETS	3,886,000	1,527,000
Current Liabilities
Accounts payable and accrued expenses	2,143,000	1,980,000
Finance lease obligations	33,000	33,000
Convertible promissory note, net of debt discount of $3,000 and $7,000	247,000	243,000
Obligation to repurchase shares	17,000	19,000
Deferred revenue	671,000	598,000
Total Current Liabilities	3,111,000	2,873,000
Long term finance lease obligations	63,000	77,000
Total Liabilities	3,174,000	2,950,000
Stockholders’ Equity (Deficit)
Common stock, $0.001 par value, 2,500,000,000 shares authorized; 7,787,441 and 6,747,441 shares issued and outstanding, respectively	8,000	7,000
Additional paid-in capital	69,435,000	66,304,000
Accumulated deficit	(68,731,000)	(67,734,000)
Total Stockholders’ Equity (Deficit)	712,000	(1,423,000)
TOTAL LIABILITIES, SHARES SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS’ EQUITY (DEFICIT)	3,886,000	1,527,000
Series C Preferred Stock [Member]
Shares Subject To Possible Redemption
Preferred stock value